A Phase 3 clinical trial testing AstraZeneca’s injection therapy benralizumab as a potential treatment for chronic obstructive pulmonary disease (COPD) has failed to meet its main goal of showing the therapy’s superiority over a placebo in terms of the ability to reduce the rate of moderate or severe COPD exacerbations. Following the trial’s negative results, […] The post Phase 3 trial testing benralizumab in COPD patients misses main goal appeared first on COPD News Today.
